ClinicaliQ Trial Snapshot
- A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT07822334.
- What is being tested: RO7830698, a novel therapeutic agent, is undergoing evaluation for safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic effects at single and multiple doses in both healthy volunteers and COPD patients.
- Patient eligibility overview: The trial recruits two populations—healthy participants without lung disease and individuals with confirmed chronic obstructive pulmonary disease—allowing assessment of drug behaviour across disease-free and diseased states.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive pulmonary disease (COPD).
Eligibility Snapshot
- : All participants: * Body mass index (BMI) between 18 and 32 kilograms per meter square (kg/m2) * Agreement to adhere to the contraception requirements Part 1: * Absence of evidence of any active or chronic disease Part 2: * Confirmed diagnosis of COPD for > 6 months, as defined by the Global Initiative for Chronic obstructive Lung Disease (GOLD) guidelines * Using maintenance inhaled therapy that may include inhaled corticosteroids (ICS) and/or long-acting β-agonist (LABA) and/or long-acting muscarinic antagonist (LAMA) as separate inhaler(s) or in combination preparation(s) * Current smoker or ex-smoker with a tobacco history of >= 10 pack years
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.